CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Gene One Life Science Delays Share Placement Payment to Nov. 26 Amid US Litigation

By Public Technologies
  • Gene One Life Science postponed payment for its KRW 15 billion private placement to Nov. 26, 2026, from Oct. 23.
  • Revolt Investment Partnership requested the delay to review the company's legal response to a US default judgment involving Inovio.
  • The company is seeking to vacate the judgment on procedural and substantive grounds.
  • New-share delivery and listing were rescheduled to Dec. 10, 2026, from Nov. 6.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gene One Life Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261023000364), on October 23, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk